Lyme Disease Diagnostic Assay - Collection of Whole Blood

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-03

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to obtain whole blood from subjects with signs and/or symptoms of early Borrelisois. Whole blood will also be obtained from subjects with suspicion of acute Borreliosis and under medical examination for Lyme disease.

In addition, whole blood will be obtained from apparently healthy subjects residing in areas endemic to Lyme disease and may also inlclude apparently healthy subjects residing in areas non-endemic to Lyme disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

NCT00001539

Lyme Disease

RECRUITING

A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease

NCT02741609

Lyme Disease

TERMINATED NA

Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis

NCT03873974

Lyme Borreliosis

COMPLETED

Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers

NCT04835792

Lyme Disease

UNKNOWN

Next Generation Sequencing Detection of Lyme Disease

NCT03505879

Lyme Disease Pediatric Infectious Disease Erythema Migrans +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Whole blood will be collected, and processed. Some blood will be transferred to additional tubes for further processing and aliquotting. Serum and plasma will be harvested and tested, at a later date, in a clinical performance study with approved and/or commercially available devices as well as an investigational Lyme assay. This study will be coordinated by the Sponsor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lyme Disease Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sick Cohort

Borreliosis Subjects - All comers expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease Borreliosis subjects with an Erythema Migrans Rash (subgroup)

Lyme diagnostic assay

Intervention Type DIAGNOSTIC_TEST

Serological and immunoresponse assay

Apparently Healthy

Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease

Lyme diagnostic assay

Intervention Type DIAGNOSTIC_TEST

Serological and immunoresponse assay

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lyme diagnostic assay

Serological and immunoresponse assay

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Signs and symptoms of acute Lyme disease which include at least one of the following:

* Recent onset of fatigue
* Skin rash
* Fever
* Muscle aches
* Neck pain
* Joint pain or lymphadenopathy

Subgroup Borreliosis Subjects- restricted signs and symptoms of acute Lyme including EM Rash

* Under physician or medical evaluation for acute on-set of Lyme Disease presenting with EM Rash
* Detailed description of the EM rash (e.g. Itchy, painful, hot, vesicular, raised) with consent for photographic documentation is required including additional picture with ruler placing to confirming size.
* EM rash with the following attributes:

* Size \> 5 cm in diameter
* Appeared 3-30 days after bite or suspected bite
* Specify Location (e.g. underarm or back of knee)
* Subjects with confirmed early localized or disseminated Lyme Borreliosis manifestation
* Signs and symptoms (e.g. Fever, Chills/Sweats, Headache, Fatigue/Tiredness, Myalgia/Sore muscles)
* The EM rash has been present \<42 days
* Clinical diagnosis of Lyme disease is suspected by the practitioner
* Ability to provide the minimum sample volume required

* Subjects having started antibiotic treatment \> 5 days before inclusion.

Healthy Subjects

* Apparently healthy subjects with no present fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, e.g. flu-like symptoms.
* Ability to provide the minimum sample volume required.

* Subjects with a recent diagnosis of Lyme disease, Anaplasmosis, Babesiosis, or history of known embedded tick bite which may have required 'manual extraction' NOTE: a tick just found on the subject or presence of a crawling tick is not considered a 'tick bite')
* Subjects currently on antibiotic treatment.
* Uncontrolled HIV-infection, if known. This is defined as an HIV-1 viral load \>40 copies/mL and/or CD4+ count \<500 x 106 cells/liter in the past 12 months.
* Active syphilis or leptospirosis, if known
* Active infection with Epstein Barr Virus (mononucleosis), if known
* Active infection with Cytomegalovirus (CMV), if known
* Subjects with autoimmune diseases, either confirmed rheumatoid arthritis and/or other autoimmune disorders diagnosed according to the leading guidelines
* Current immunomodulation mediation including \>7.5 mg prednisone daily, methotrexate, and/or biologicals. Medications such as hydroxychloroquine, sulfasalazine or NSAIDs are acceptable.
* Immunodeficiency, hematologic malignancies in the medical history
* Chemotherapy during the past year